Retatrutide, a new triple-agonist peptide drug from Eli Lilly, is showing remarkable results in clinical trials. It targets GLP-1, GIP, and glucagon receptors, leading to significant fat loss (average 37 lbs in 40 weeks), reduced liver fat (80%), improved A1C levels, and decreased cholesterol and triglycerides. It also appears to preserve muscle mass and may have anti-aging and anti-inflammatory benefits. While projected for FDA approval in mid-2027, its potential extends beyond obesity and diabetes to broader health and wellness applications, sparking immense hype.
Impact: High. Retatrutide represents a potential paradigm shift in metabolic health and aging, offering unprecedented efficacy that could redefine treatment for obesity, diabetes, and related conditions.
In the source video, this keypoint occurs from 00:58:36 to 01:04:09.
Sources in support: David Friedberg (Host)

